AGC Biologics announces plans for New Manufacturing Site in Yokohama Japan

The new four-story 20,000 m² facility will feature mammalian cell culture, messenger RNA and cell therapy services and be operational in 2026  Today, we announced plans to construct a new manufacturing facility at AGC Inc.’s Yokohama Technical Center in Japan. The new site is a part of our strategic growth strategy to create more high-quality […]

MBrace Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial Evaluating Investigational Antibody-Drug Conjugate MBRC-101

SAN DIEGO (December 19, 2023) – MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the successful initiation of patient dosing in its Phase 1/1b study evaluating MBRC-101 in patients with advanced metastatic solid tumors refractory to standard treatment. […]

AGC Biologics to Prepare Late-Phase and Commercial Runs for Immunocore

Global CDMO’s Heidelberg site to support Process Performance Qualification for IMC-F106C late-stage program and prepare for commercial readiness. Today, we announced a new late-stage clinical and process performance qualification (PPQ) project at our Heidelberg, Germany site with Immunocore Holdings Plc (Nasdaq: IMCR). Immunocore intends to use the Heidelberg site to complete late-stage manufacturing and prepare for […]

Federal Jury Finds Guardant Health Willfully Infringes University of Washington Duplex Sequencing Patents Exclusively Licensed to TwinStrand Biosciences, Inc., Awards $83.4M in Damages; PTAB Rejects Invalidity Arguments on UW Patents

SEATTLE, Nov. 15, 2023 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from residual cancer detection to genetic toxicology, announced a successful jury verdict in the federal patent infringement case it brought with the University of Washington against Guardant Health. The jury found that […]

Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

Nov 28, 2023 AURORA, Colo., Nov. 8, 2023 /PRNewswire/ – Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seq™ technology will be presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California. Four of these studies have been […]

Ultivue announces launch of new configurable multiplex spatial panels at the Society for Immunotherapy of Cancer 2023 meeting

Oct 30, 2023 CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ — Ahead of the 38th annual meeting of the Society for Immunotherapy of Cancer (SITC), Ultivue today announced the launch of OmniVUE™, a unique portfolio of fully customizable biomarker panels for multiplex immunofluorescence analysis of the tumor immune microenvironment. Researchers can now select any combination of up to 8 […]

AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product

Today we announced a new service agreement with Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard). Under the agreement, AGC Biologics is providing autologous production for a next-generation -therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.   With the product currently in the pre-clinical phase, AGC […]

TwinStrand Biosciences Announces Executive Leadership Changes to Accelerate Adoption of Duplex Sequencing for Minimal Residual Disease (MRD) Testing for Hematological Malignancies and Cell Therapy Monitoring

SEATTLE, Aug. 29, 2023 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from residual cancer detection to genetic toxicology announced the appointment of Ron Andrews, as Chief Executive Officer and Board Member. TwinStrand® is also pleased to announce that David Canner, Partner at Soleus […]

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform

Apr 27, 2023 AURORA, Colo., April 27, 2023 /PRNewswire/ — Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University… Read the full article […]